A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01878617
Recruitment Status : Recruiting
First Posted : June 17, 2013
Last Update Posted : September 18, 2018
Genentech, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
St. Jude Children's Research Hospital

No Study Results Posted on for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : June 2023
  Estimated Study Completion Date : December 2026